Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,885.65
(
0.59%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
95.26
(
-0.74%
)
Bitcoin
66,543.49
(
-6.75%
)
News Focus
News Focus
Post# of 257692
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123055
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 117156

Monday, 04/04/2011 5:16:56 PM

Monday, April 04, 2011 5:16:56 PM

Post# of 257692
Are hostile biotech takeovers becoming more common?


The five largest initially-hostile drug/biotech deals: 
 Acquired                    Deal 
 Company            Buyer    Value  Date  Notes 
 Sanofi-Synthélabo  Aventis  $71B   1/04  Billed as merger of =’s. 
 Genentech          Roche    $47B   7/08  For 46% not owned. 
 GENZ               SNY      $20B   8/10  Excl. contingent rights. 
 Chiron             NVS      $5.9B  9/05  For 54% not owned. 
 CEPH               VRX      $5.7B  3/11  Proposed deal.

Source: http://www.ft.com/cms/s/0/65661f04-5e44-11e0-b1d8-00144feab49a.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today